- Everolimus+bevacizumab fails to improve response rate vs historical response with bevacizumab alone in patients with recurrent ovarian, peritoneal, and fallopian tube cancer.
- Long-term responders show alterations in the phosphoinositide 3-kinase (PI3K) pathway.
Why this matters
- Recurrent ovarian cancer has poor prognosis and warrants novel therapeutic approaches.
- Phase 2 study of 50 patients (median age, 60.5 years) with recurrent ovarian, peritoneal, and fallopian tube cancer.
- Patients received oral everolimus daily and intravenous bevacizumab every 14 days on a 28-day cycle.
- Funding: None disclosed.
- Median number of treatment cycles completed: 4.
- 24% of patients (adjusted) were progression-free at 6 months.
- The adjusted median PFS was 3.67 months.
- 76% of patients discontinued treatment due to disease progression.
- 2.2% of patients achieved a complete response, 13.0% had a partial response, and 76.1% had stable disease.
- 25 patients experienced a total of 31 grade 3 adverse events.
- 2 grade 4 toxicities were reported.
- Long-term responders with clear cell carcinomas had alterations in the PI3K pathway.
- Open-label design.